Turkey says China's CoronaVac efficacy 91.25%, likely to increase
ANKARA, December 24 (Reuters). A COVID-19 vaccine developed by China's Sinovac Biotech is 91.25% effective and rates are likely to rise based on data from late-stage studies, Turkish researchers said Thursday as the country becomes the second study website to provide results for the Chinese candidate to produce.
The researchers, who are part of the government's Science Council, said no major symptoms were noted during CoronaVac's trials in Turkey, other than one person who had an allergic reaction.
Turkey had agreed to source 50 million cans of CoronaVac from Sinovac by December 11, but shipping was delayed. Health Minister Fahrettin Koca said the vaccines would arrive in Turkey on Monday, adding that Turkey would vaccinate around 9 million people in the first group, starting with health workers. (Reporting by Tuvan Gumrukcu and Ali Kucukgocmen; Editing by Alex Richardson)
Scroll to continue with the content
Microsoft and Redis
Meet the fast and fully managed in-memory data store.
Don't miss the opportunity to hear the unique perspectives from Microsoft and partner specialists and learn more about Azure Cache for Redis.
In this article
You should check here to buy the best price guaranteed products.
CDC panel approves Moderna and J&J boosters
Adam Schiff Is Worried About American Democracy | FiveThirtyEight Politics Podcast
Nightly NBA Parlay: stacking the best bets for Thursday’s slate
Justin Bieber Does Viral TikTok Trend With Coi Leray!
Here's why the Knicks could be scary in the postseason | Carton & Roberts
'I've lost my joy': Anti-vax Republican, who worked for the Trump campaign and embraced QAnon, says she has COVID-19